SCHEMBL378727

SCHEMBL378727

COC(=O)Cn1ncc2cc(Oc3ccc(F)cc3C#N)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.43
SLC22A12 Q96S37 11/20 0.42
MAP4K4 O95819 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
FYN P06241 1/20 0.40
LYN P07948 1/20 0.40
RET P07949 1/20 0.40
BCR P11274 1/20 0.40
FGFR1 P11362 1/20 0.40
BRAF P15056 1/20 0.40
EPHA1 P21709 1/20 0.40
EPHA2 P29317 1/20 0.40
ABL2 P42684 1/20 0.40
FRK P42685 1/20 0.40
MAPK9 P45984 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
IRAK1 P51617 1/20 0.40
MAPK10 P53779 1/20 0.40
EPHB3 P54753 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12216030 0.90 MAP4K4 (0.40) SLC22A12MAP4K4ABL1NTRK1FYN
SCHEMBL2441913 0.88 GRIN2B (0.41) SLC22A12MAP4K4ABL1NTRK1FYN
SCHEMBL12233232 0.85 SYK (0.43) SYKMAP4K4ABL1NTRK1FYN
SCHEMBL12216027 0.83 MAP4K4 (0.46) SYKMAP4K4ABL1NTRK1FYN
SCHEMBL12216031 0.83 AR (0.41) SLC22A12MAP4K4ABL1NTRK1FYN
SCHEMBL379029 0.83 MAP4K4 (0.46) SYKSLC22A12MAP4K4ABL1NTRK1
Hydrochloric Acid SCHEMBL379388 0.83 MAP4K4 (0.45) SYKMAP4K4ABL1NTRK1FYN
SCHEMBL2446966 0.82 AR (0.41) SLC22A12MAP4K4ABL1NTRK1FYN
SCHEMBL378721 0.82 HTR2A (0.46) SLC22A12MAP4K4ABL1NTRK1FYN
SCHEMBL2440738 0.82 HTR2A (0.50) SLC22A12MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790206-B2 Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof ARRAY BIOPHARMA INC. (US) 2017-10-17 US disclosed
US-9790206-B2 Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof ARRAY BIOPHARMA INC. (US) 2017-10-17 US disclosed
US-9790206-B2 Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof ARRAY BIOPHARMA INC. (US) 2017-10-17 US disclosed
EP-2961744-B1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF ARRAY BIOPHARMA INC (US) 2017-06-28 EP disclosed
EP-2961744-B1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF ARRAY BIOPHARMA INC (US) 2017-06-28 EP disclosed
US-20160002210-A1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF ARRAY BIOPHARMA INC. (US) 2016-01-07 US disclosed
US-20160002210-A1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF ARRAY BIOPHARMA INC. (US) 2016-01-07 US disclosed
US-20160002210-A1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF ARRAY BIOPHARMA INC. (US) 2016-01-07 US disclosed
EP-2961744-A1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Array Biopharma, Inc. (US) 2016-01-06 EP disclosed
WO-2014134313-A1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF ARRAY BIOPHARMA INC. (US) 2014-09-04 WO disclosed
US-20110124878-A1 KINASE INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-05-26 US disclosed
US-20110124878-A1 KINASE INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-05-26 US disclosed
US-20110124878-A1 KINASE INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-05-26 US disclosed
US-20100331385-A1 PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-12-30 US disclosed
WO-2009015000-A1 PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-01-29 WO disclosed
US-20090023795-A1 Kinase Inhibitors And Methods Of Use Thereof ARRAY BIOPHARMA, INC. 2009-01-22 US disclosed
US-20090023795-A1 Kinase Inhibitors And Methods Of Use Thereof ARRAY BIOPHARMA, INC. 2009-01-22 US disclosed
US-20090023795-A1 Kinase Inhibitors And Methods Of Use Thereof ARRAY BIOPHARMA, INC. 2009-01-22 US disclosed
EP-1981851-A1 KINASE INHIBITORS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-10-22 EP disclosed
WO-2007089646-A1 KINASE INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023795-A1 Kinase Inhibitors And Methods Of Use Thereof MAP3K1, MAP3K19, MAP3K20 SYK 306/4885SLC22A12 2930/4885MAP4K4 31/4885
US-20110124878-A1 KINASE INHIBITORS AND METHODS OF USE THEREOF MAP3K19, MAP3K2, MAP3K20 SYK 380/4885SLC22A12 2466/4885MAP4K4 27/4885
US-20160002210-A1 INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF CYP3A7, CYP3A5, CYP3A43 SYK 1483/4885SLC22A12 3300/4885MAP4K4 1332/4885
US-20100331385-A1 PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS MAP3K1, MAP3K19, MAP3K13 SYK 1012/4885SLC22A12 4127/4885MAP4K4 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.